Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

シメチジンとパラチロイド性多発症

G Graziani, A Aroldi, G Colussi

    Lancet (London, England)
    |May 24, 1980
    PubMed
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    関連する概念動画

    こちらも読む

    関連記事

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    並び替え
    Same author

    RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

    ESMO open·2025
    Same author

    Idiopathic erythrocytosis: a germline disease?

    Clinical and experimental medicine·2024
    Same author

    Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?

    ESMO open·2024
    Same author

    Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.

    Breast cancer research and treatment·2023
    Same author

    Evaluation of Levothyroxine Bioavailability after Oral Administration of a Fixed Combination of Soy Isoflavones in Post-menopausal Female Volunteers.

    Drug research·2015
    Same author

    Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer.

    Minerva ginecologica·2012
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    関連記事をすべて見る